ZD 6126
Alternative Names: ANG-453; ZD-6126Latest Information Update: 07 Jul 2011
At a glance
- Originator Angiogene Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 14 Feb 2005 A preclinical study has been added to the Cancer pharmacodynamics section
- 03 Aug 2004 Preclinical studies in Solid tumours in the US - due to unexpected toxicity findings from phase II studies, ZD 6126 is now undergoing preclinical studies to explore scheduling options
- 09 Oct 2003 Data presented at the 12th European Conference of Clinical Oncology (ECCO-2003) have been added to the pharmacokinetics and adverse events sections